SLXN vs PET Comparison

Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.

Wag Group Co develops and supports a proprietary marketplace technology platform available as a website and mobile app that enables independent Pet Caregivers to connect with pet parents. The platform allows pet parents to make pet service requests in the platform, which can then be fulfilled by Pet Caregivers. Wag supports dog walking, pet sitting, pet boarding, drop-in visits at the pet parent's home, advice from licensed pet experts, training services, pet insurance comparison tools and pet wellness plans.